Alvotech re­sub­mits its in­ter­change­able Hu­mi­ra biosim­i­lar as Ab­b­Vie clings to brand dom­i­nance

Bil­lion­aire Alvotech CEO Róbert Wess­man told in­vestors on Thurs­day that the com­pa­ny has re­sub­mit­ted its Hu­mi­ra in­ter­change­able biosim­i­lar ap­pli­ca­tion to the FDA af­ter re­ceiv­ing a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER